CLAIMS

1. An antibody, comprising a first immunoglobulin chain and a second immunoglobulin chain, wherein the first chain, which is a light chain, and the second chain, which is a heavy chain, contain, respectively, SEQ ID NOs: 7-9 and SEQ ID NOs: 10-12; or SEQ ID NOs: 13-15 and SEQ ID NOs: 16-18.

2. The antibody of claim 1, wherein the light chain and the heavy chain contain, respectively, SEQ ID NOs: 7-9 and SEQ ID NOs: 10-12.

3. The antibody of claim 1, wherein the light chain and the heavy chain contain, respectively, SEQ ID NOs: 13-15 and SEQ ID NOs: 16-18.

4. The antibody of claim 1, wherein the antibody comprises the light chain variable region of SEQ ID NO: 21 and the heavy chain variable region of SEQ ID NO: 22, or the light chain variable region of SEQ ID NO: 23 and the heavy chain variable region of SEQ ID NO: 24.

5. The antibody of claim 4, wherein the antibody comprises the light chain variable region of SEQ ID NO: 21 and the heavy chain variable region of SEQ ID NO: 22.

6. The antibody of claim 4, wherein the antibody comprises the light chain variable region of SEQ ID NO: 23 and the heavy chain variable region of SEQ ID NO: 24.

7. The antibody of any one of claims 1 to 6, wherein the antibody binds to human P-Selectin Glycoprotein Ligand 1, wherein the antibody upon binding to P-Selectin Glycoprotein Ligand 1 on an activated T-cell induces death of the activated T-cell.

8. An antibody that binds specifically to amino acid residues 50-60 of human P-Selectin Glycoprotein Ligand 1, wherein the antibody includes a light chain and a heavy chain containing, respectively, SEQ ID NOs: 7-9 and SEQ ID NOs: 10-12 or SEQ ID NOs: 13-15 and SEQ ID NOs: 16-18.

9. The antibody of claim 8, wherein the antibody binds to human P-Selectin Glycoprotein Ligand 1, wherein the antibody, upon binding to P-Selectin Glycoprotein Ligand 1 on an activated T-cell, induces the death of the activated T-cell.

10. An isolated nucleic acid comprising a sequence encoding a polypeptide comprising SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18.

11. An isolated nucleic acid comprising a sequence encoding a polypeptide comprising SEQ ID NOs: 21, 22, 23, or 24.

12. A vector comprising the nucleic acid of claim 10.

13. A vector comprising the nucleic acid of claim 11.

14. A host cell comprising a nucleic acid of claim 10.

15. The host cell of claim 14, wherein the cell is a bacterial cell, a yeast cell, a plant cell, an insect cell, or a mammalian cell.

16. The host cell of claim 15, wherein the mammalian cell is a hybridoma cell.

17. An isolated nucleic acid comprising a sequence encoding a polypeptide comprising: SEQ ID NOs: 7-9, SEQ ID NOs: 10-12, SEQ ID NOs: 13-15, or SEQ ID NOs: 16-18.

18. A vector comprising the nucleic acid of claim 17.

19. A host cell comprising a nucleic acid of claim 17.

20. The host cell of claim 19, wherein the cell is a bacterial cell, a yeast cell, a plant cell, an insect cell, or a mammalian cell.

21. The host cell of claim 20, wherein the mammalian cell is a hybridoma cell.

22. A host cell comprising a nucleic acid of claim 11.

23. The host cell of claim 22, wherein the cell is a bacterial cell, a yeast cell, a plant cell, an insect cell, or a mammalian cell.

24. The host cell of claim 23, wherein the mammalian cell is a hybridoma cell.

25. An antibody according to any one of claims 1 to 9, wherein the antibody is a chimeric antibody.

26. An antibody according to any one of claims 1 to 9, wherein the antibody is a humanized antibody.

27. An isolated antibody that binds specifically to human P-Selectin Glycoprotein Ligand 1, wherein the antibody comprises (i) a light chain comprising a variable region of SEQ ID NO: 21 or SEQ ID NO: 23 linked to a human kappa light chain constant region, and a heavy chain comprising a variable region of SEQ ID NO: 22 or SEQ ID NO: 24.

28. The antibody of claim 27, wherein the antibody comprises a heavy chain constant region of human IgG1, IgG2 or IgG4.

29. A composition comprising the antibody according to any one of claims 1 to 9 or any one of claims 25 to 28.

30. Use of an antibody of any one of claims 1 to 9 or any one of claims 25 to 28 in the preparation of a medicament for inducing death of an activated T cell.

31. Use of an antibody of any one of claims 1 to 9 or any one of claims 25 to 28 in the preparation of a medicament for modulating a T cell-mediated immune response.

WHAT IS CLAIMED IS:

1. An immunoglobulin chain comprising, respectively, SEQ ID NOs: 1-3, SEQ ID NOs: 4-6, SEQ ID NOs: 7-9, SEQ ID NOs: 10-12, SEQ ID NOs: 13-15, or SEQ ID NOs: 16-18.

2. The immunoglobulin chain of claim 1, wherein the immunoglobulin chain contains SEQ ID NOs: 1-3 or SEQ ID NOs: 4-6.

3. The immunoglobulin chain of claim 1, wherein the immunoglobulin chain contains SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, or 26.

4. The immunoglobulin chain of claim 3, wherein the immunoglobulin chain contains SEQ ID NO: 25 or 26.

5. An antibody, comprising a first immunoglobulin chain of claim 1 and a second immunoglobulin chain also of claim 1, wherein the first chain, which is a light chain, and the second chain, which is a heavy chain, contain, respectively, SEQ ID NOs: 7-9 and SEQ ID NOs: 10-12; or SEQ ID NOs: 13-15 and SEQ ID NOs: 16-18.

6. The antibody of claim 5, wherein the light chain and the heavy chain contain, respectively, SEQ ID NOs: 19 and 20, 21 and 22, or 23 and 24.

7. An antibody that binds specifically to amino acid residues 115-126 of human P-Selectin Glycoprotein Ligand 1 (PSGL-1).

8. The antibody of claim 7, wherein the antibody binds specifically to amino acid residues 117-123.

9. The antibody of claim 8, wherein the antibody binds specifically to amino acid residues 119-121.

10. The antibody of claim 7, wherein the antibody, upon binding to P-Selectin Glycoprotein Ligand 1 (PSGL-1) on an activated T-cell, induces the death of the activated T-cell.

11. A method of inducing death of an activated T-cell, comprising contacting an antibody of claim 7 with an activated T cell, wherein binding of the antibody to the activated T cell induces death of the activated T cell.

12. A method of modulating a T cell-mediated immune response in a subject, the method comprising:

identifying a subject having or being at risk of having a condition related to an excessive T cell-mediated immune response, and

administering to the subject an effective amount of an antibody of claim 7.

13. The method of claim 12, wherein the condition is an inflammatory disease, an autoimmune disease, an allergic disease, or a T cell cancer.

14. The method of claim 13, wherein the subject has received or is contemplated to receive an allogeneic or xenogeneic transplant.

15. An isolated nucleic acid comprising a sequence encoding the immunoglobulin chain of claim 1.

16. An isolated nucleic acid comprising a sequence encoding the immunoglobulin chain of claim 3.

17. A vector comprising the nucleic acid of claim 15.

18. A vector comprising the nucleic acid of claim 16.

19. A host cell comprising a nucleic acid encoding SEQ ID NOs: 1-3, SEQ ID NOs: 4-6, SEQ ID NOs: 7-9, SEQ ID NOs: 10-12, SEQ ID NOs: 13-15, or SEQ ID NOs:

16-18.

20. The host cell of claim 19, wherein the cell is a bacterial cell, a yeast cell, a plant cell, an insect cell, or a mammalian cell.

21. The host cell of claim 20, wherein the mammalian cell is a hybridoma cell.

22. A host cell comprising a nucleic acid encoding SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, or 26.

23. The host cell of claim 22, wherein the cell is a bacterial cell, a yeast cell, a plant cell, an insect cell, or a mammalian cell.

24. The host cell of claim 23, wherein the mammalian cell is a hybridoma cell.